[go: up one dir, main page]

MX2017001863A - Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion. - Google Patents

Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion.

Info

Publication number
MX2017001863A
MX2017001863A MX2017001863A MX2017001863A MX2017001863A MX 2017001863 A MX2017001863 A MX 2017001863A MX 2017001863 A MX2017001863 A MX 2017001863A MX 2017001863 A MX2017001863 A MX 2017001863A MX 2017001863 A MX2017001863 A MX 2017001863A
Authority
MX
Mexico
Prior art keywords
glucocorticoid
neovascularization
prevention
allograft rejection
loaded nanoparticles
Prior art date
Application number
MX2017001863A
Other languages
English (en)
Inventor
Wang Bing
Scot Hanes Justin
Pan Qing
Xu Qingguo
J Boyland Nicholas
J Stark Walter
Luo Lixia
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2017001863A publication Critical patent/MX2017001863A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Partículas que encapsulan un glucocorticoide tal como fosfato de sodio dexametasona (DSP) en una matriz tal como poli(ácido láctico-co-glicólico) (PLGA) biodegradable que se recubre densamente con polímero hidrofílico tal como PEG o PLURONIC(r) F127, exhiben liberación sostenida de DSP por hasta 7 días in vitro. Estas nanopartículas se pueden utilizar para prevenir el rechazo de injerto corneal o la neovascularización corneal.
MX2017001863A 2014-08-13 2015-08-03 Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion. MX2017001863A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462037000P 2014-08-13 2014-08-13
US201562139561P 2015-03-27 2015-03-27
PCT/US2015/043478 WO2016025215A1 (en) 2014-08-13 2015-08-03 Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization

Publications (1)

Publication Number Publication Date
MX2017001863A true MX2017001863A (es) 2017-07-17

Family

ID=54011072

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001863A MX2017001863A (es) 2014-08-13 2015-08-03 Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion.

Country Status (8)

Country Link
US (1) US10195212B2 (es)
EP (1) EP3193827A1 (es)
JP (1) JP2017524712A (es)
KR (1) KR20170046146A (es)
CN (1) CN106794152A (es)
CA (1) CA2957764C (es)
MX (1) MX2017001863A (es)
WO (1) WO2016025215A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2016100086A1 (en) 2014-12-15 2016-06-23 The Johns Hopkins University Cvs transplantation for treatment of bacterial vaginosis
RU2729731C2 (ru) 2014-12-15 2020-08-11 Зе Джонс Хопкинс Юниверсити Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
US9808531B2 (en) 2015-09-22 2017-11-07 Graybug Vision, Inc. Compounds and compositions for the treatment of ocular disorders
EA038755B1 (ru) 2015-11-12 2021-10-14 Грейбаг Вижн, Инк. Агрегирующие микрочастицы для обеспечения замедленного высвобождения терапевтического агента для внутриглазной доставки
DE102017002454A1 (de) * 2017-03-14 2018-09-20 Friedrich-Schiller-Universität Jena Organische Polymerpartikel enthaltend Poly(oxazolin)-Stabilisatoren und Verwendung von Poly(oxazolinen) zur Stabilisierung von organischen Polymerpartikeln
WO2018175922A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
JP2020519585A (ja) 2017-05-10 2020-07-02 グレイバグ ビジョン インコーポレイテッド 医学療法のための延長放出マイクロ粒子及びその懸濁液
WO2019071275A1 (en) * 2017-10-06 2019-04-11 Aciont Inc. DEVICES FOR DELIVERY OF NON-INVASIVE OCULAR MEDICINE
US20220175687A1 (en) * 2019-04-11 2022-06-09 The Johns Hopkins University Nanoparticles for drug delivery to brain
WO2021168239A1 (en) * 2020-02-21 2021-08-26 The Johns Hopkins University Suprachoroidal delivery of drug particles to reduce toxicity

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US4888176A (en) 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
CA2518223A1 (en) * 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Intravenous nanoparticles for targeting drug delivery and sustained drug release
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20050226814A1 (en) 2004-04-13 2005-10-13 Bausch & Lomb Incorporated Diagnostic method and kit for implantation of a sustained release drug-delivery implant with a steroid
US20060089590A1 (en) * 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
JP2007001926A (ja) * 2005-06-24 2007-01-11 Ltt Bio-Pharma Co Ltd 吸入・噴霧用ステロイド製剤
US8916206B2 (en) * 2005-12-26 2014-12-23 Ltt Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
EP2156848A4 (en) * 2007-05-14 2012-11-28 Ltt Bio Pharma Co Ltd NANOPARTICLE CONTAINING A LOW MOLECULAR WEIGHT DRUG HAVING A NEGATIVELY PROLONGED RELEASE GROUP
CN101970042A (zh) * 2008-02-25 2011-02-09 眼门药品公司 经由离子电渗法增强递送治疗药物至眼部组织
US20110206773A1 (en) 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
EP2482818A4 (en) 2009-09-29 2014-04-09 Eyegate Pharmaceuticals Inc POSITIVELY CHARGED POLY (D, L-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES AND METHODS OF MAKING SAME
CN103930115A (zh) 2011-09-13 2014-07-16 阿尔塔克有限公司 药物纳米粒组合物
RU2598627C2 (ru) * 2012-01-19 2016-09-27 Дзе Джонс Хопкинс Юниверсити Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки
NZ741873A (en) * 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport

Also Published As

Publication number Publication date
CA2957764C (en) 2019-07-02
JP2017524712A (ja) 2017-08-31
CA2957764A1 (en) 2016-02-18
US10195212B2 (en) 2019-02-05
US20170157147A1 (en) 2017-06-08
KR20170046146A (ko) 2017-04-28
EP3193827A1 (en) 2017-07-26
CN106794152A (zh) 2017-05-31
WO2016025215A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
MX2017001863A (es) Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion.
MY190392A (en) A delayed release drug formulation
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
CO2017007003A2 (es) Formulaciones de sunitinib y métodos para uso de las mismas en el tratamiento de trastornos oculares
ECSP10010538A (es) Preparacion solida de desintegracion oral
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
NZ700875A (en) Pharmaceutical nanoparticles showing improved mucosal transport
PH12021550603A1 (en) Compositions and methods of manufacturing protein microparticles
CO2017012573A2 (es) Formación de nanopartículas de ciclosporina a/ciclodextrina
AT515178A5 (de) Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie
NZ739674A (en) Liquid polymer delivery system for extended administration of drugs
MX2018005971A (es) Composicion farmaceutica novedosa que comprende particulas que comprenden un complejo de un polirribonucleotido de hebra doble y una polialquilenimina.
EP3494959A3 (en) Sustained release latanoprost implant
WO2015152693A3 (ko) 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
WO2013013038A3 (en) Doping agents and polymeric compositions thereof for controlled drug delivery
AR095544A1 (es) Un agente de sostén
MX2020012736A (es) Agentes de liberacion de gas antimicrobianos y sistemas y metodos para utilizarlos.
WO2015099985A3 (en) Cationic materials and formulations for drug delivery
MX2016001607A (es) Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas.
PH12014502834B1 (en) Pharmaceutical form for extended release of active substances
WO2016040814A3 (en) Disulfide polymers and methods of use
WO2012092486A3 (en) Modified release benzimidazole formulations
MX2017001903A (es) Suministro de antioxidantes bioactivos, nanoencapsulados.
PH12016500869A1 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant